4HY4

Crystal structure of cIAP1 BIR3 bound to T3170284


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.249 Å
  • R-Value Free: 0.170 
  • R-Value Work: 0.152 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Design and Synthesis of Potent Inhibitor of Apoptosis (IAP) Proteins Antagonists Bearing an Octahydropyrrolo[1,2-a]pyrazine Scaffold as a Novel Proline Mimetic.

Hashimoto, K.Saito, B.Miyamoto, N.Oguro, Y.Tomita, D.Shiokawa, Z.Asano, M.Kakei, H.Taya, N.Kawasaki, M.Sumi, H.Yabuki, M.Iwai, K.Yoshida, S.Yoshimatsu, M.Aoyama, K.Kosugi, Y.Kojima, T.Morishita, N.Dougan, D.R.Snell, G.P.Imamura, S.Ishikawa, T.

(2013) J.Med.Chem. 56: 1228-1246

  • DOI: 10.1021/jm301674z
  • Primary Citation of Related Structures:  4HY0, 4HY5

  • PubMed Abstract: 
  • To develop novel inhibitor of apoptosis (IAP) proteins antagonists, we designed a bicyclic octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline bioisostere. This design was based on the X-ray co-crystal structure of four N-terminal amino acid ...

    To develop novel inhibitor of apoptosis (IAP) proteins antagonists, we designed a bicyclic octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline bioisostere. This design was based on the X-ray co-crystal structure of four N-terminal amino acid residues (AVPI) of the second mitochondria-derived activator of caspase (Smac) with the X-chromosome-linked IAP (XIAP) protein. Lead optimization of this scaffold to improve oral absorption yielded compound 45, which showed potent cellular IAP1 (cIAP1 IC(50): 1.3 nM) and XIAP (IC(50): 200 nM) inhibitory activity, in addition to potent tumor growth inhibitory activity (GI(50): 1.8 nM) in MDA-MB-231 breast cancer cells. X-ray crystallographic analysis of compound 45 bound to XIAP and to cIAP1 was achieved, revealing the various key interactions that contribute to the higher cIAPI affinity of compound 45 over XIAP. Because of its potent IAP inhibitory activities, compound 45 (T-3256336) caused tumor regression in a MDA-MB-231 tumor xenograft model (T/C: -53% at 30 mg/kg).


    Organizational Affiliation

    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Baculoviral IAP repeat-containing protein 2
A, B
115Homo sapiensGene Names: BIRC2 (API1, IAP2, MIHB, RNF48)
EC: 6.3.2.-
Find proteins for Q13490 (Homo sapiens)
Go to Gene View: BIRC2
Go to UniProtKB:  Q13490
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZN
Query on ZN

Download SDF File 
Download CCD File 
A, B
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
1BG
Query on 1BG

Download SDF File 
Download CCD File 
A, B
(3S,8aR)-2-{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl}-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]octahydropyrrolo[1,2-a]pyrazine-3-carboxamide
C30 H45 N5 O3
STMKHYWFPMLFAV-PWZZVKMOSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
1BGIC50: 2.1 nM BINDINGMOAD
1BGIC50: 2.7 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.249 Å
  • R-Value Free: 0.170 
  • R-Value Work: 0.152 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 30.645α = 90.00
b = 68.591β = 90.00
c = 117.592γ = 90.00
Software Package:
Software NamePurpose
MOLREPphasing
HKL-2000data scaling
HKL-2000data reduction
HKL-2000data collection
REFMACrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2013-01-30
    Type: Initial release
  • Version 1.1: 2013-02-27
    Type: Database references
  • Version 1.2: 2013-08-07
    Type: Non-polymer description, Structure summary
  • Version 1.3: 2015-09-09
    Type: Structure summary